MN-ASI-DATAMYTE
11.12.2015 11:01:06 CET | Business Wire | Press release
ASI DATAMYTE, Inc., the leader in global quality management solutions, announces today a multinational partnership with NEXTSENSE GmbH, the leader in the production of laser-based profile measurement solutions for manufacturers, worldwide. The automotive industry is evolving with more complex designs using a broader variety of materials; which is creating the need for a more comprehensive measurement solutions for ensuring accuracy, inspection thoroughness and operator repeatability. As part of this new relationship, ASI DATAMYTE will now support this market need by offering CALIPRI product line to the automotive industry.
“CALIPRI is one of the fastest-growing, scalable, non-contact measurement solutions in the market,” said Sven Tetzlaff, ASI DATAMYTE GmbH head of product and general manager. “We are confident the combination of CALIPRI and our expertise, technology and client base, creates unmatched value for automotive companies looking to produce higher quality products. We will now have a streamlined solution using one technology supporting the inline and automated measurement throughout the production process.”
“We are committed to continuing our investments and innovation in our state-of-the-art optical sensor technology that will empower the future of ASI DATAMYTE’s clients and distributors,” said Clemens Gasser, chief executive officer, NEXTSENSE GmbH. “We are looking forward to watching our partnership redefine quality measurement and data collection across the globe.”
About ASI DATAMYTE
ASI DATAMYTE Inc. provides integrated software, hardware and services for driving best-in-class quality in manufacturing. Refining its solutions for more than 40 years, ASI DATAMYTE is serving the largest, most prestigious manufacturers with localized solutions on a global basis. ASI DATAMYTE is headquartered in Plymouth, MN, with offices and support centers in more than 40 countries.
About NEXTSENSE
NEXTSENSE GmbH is a global leader in producing and distributing revolutionary solutions for profile measurement and surface inspection, called CALIPRI and SURFILES. All solutions are based on non-contact measurement technology which captures unbiased measurement data removing all outside variables based on differences between operators or environmental conditions. NEXTSENSE devices are used for gap and flush measurement of automotive bodies, wear measurement of railway wheelsets and analyzing the surfaces of rolled steel. The client list ranges from international automobile manufactures (e.g. Volkswagen, Toyota, General Motors) to well-known international enterprises in the railway, steel and technology industry such as SNCF, AcelorMittal and Miele).
View source version on businesswire.com: http://www.businesswire.com/news/home/20151211005140/en/
Contact:
ASI DATAMYTE Inc.
Mary Braunwarth
mary.braunwarth@asidatamyte.com
+1.763.553.0455
info@asidatamyte.com
www.asidatamyte.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom